Key clinical point: Avacopan is efficacious and safe for treating antineutrophil cytoplasmic antibody–associated vasculitis.
Major finding: Avacopan was noninferior to prednisone regarding the week 26 rate of disease remission (72.3% vs. 70.1%; P < .0001 for noninferiority) and was superior regarding the week 52 rate of sustained disease remission (65.7% vs. 54.9%; P = .0066 for superiority).
Study details: The phase 3, double-blind, randomized, controlled ADVOCATE trial among 331 patients with antineutrophil cytoplasmic antibody–associated vasculitis comparing avacopan with prednisone, each combined with rituximab or with cyclophosphamide followed by azathioprine.
Disclosures: The trial was sponsored by ChemoCentryx. Dr. Merkel disclosed receiving grant/research support and consulting fees from ChemoCentryx, among other disclosures. Dr. Lally disclosed that she was an investigator in the trial.
Merkel PA et al. Ann Rheum Dis. 2020;79[suppl 1]:8, Abstract OP0011.